Urtoxazumab (3.0 mg/kg) vs placebo
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
- Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 71 participantsLow